ReviewFrontiers in pharmacology2019
Review of Statistical Methodologies for Detecting Drug-Drug Interactions Using Spontaneous Reporting Systems.
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 91 citations in OpenAlex.
- Possible clinical drug interactions between ticagrelor and concomitant medications: for adverse drug event monitoring in real-world.Cardiovascular drugs and therapy · 2026Article
- Article
- The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- PregMedNet: Multifaceted maternal medication impacts on neonatal complications.Nature communications · 2026Article
- Disproportionality Analysis and Timing of Drug-Associated Guillain-Barré Syndrome Onset Based on the Japanese Adverse Drug Event Report Database.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Drug-drug interaction signals between carbonic anhydrase inhibitors and vitamin D preparations in urinary tract stones: disproportionality analysis evaluation from Japanese spontaneous reports of adverse events.Journal of pharmaceutical health care and sciences · 2026Article
- Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance.International journal of molecular sciences · 2026Article
- Disproportionality analysis and "perpetrator" or "accomplice" review of Baloxavir marboxil in public FAERS database.BMC infectious diseases · 2026Article
- Signal mining and safety profile analysis of lapatinib: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.Journal of pharmaceutical policy and practice · 2026Article
- Exploratory assessment of bleeding risk associated with concurrent use of Anti-VEGF agents and anticoagulants in oncology.Frontiers in pharmacology · 2026Article
- Differential fracture risk among proton pump inhibitors in older adults: evidence network and pharmacovigilance validation.Frontiers in pharmacology · 2026Article
- Absence of pharmacovigilance signals for bleeding events associated with warfarin-SSRI drug interactions: a comparative analysis of FAERS and CVARD databases.Therapeutic advances in drug safety · 2026Article
- Drug-drug interactions between sex hormones and analgesics linked to thromboembolic events: an FDA adverse event reporting system analysis.Frontiers in pharmacology · 2026Article
- Comprehensive pharmacovigilance assessment of pairwise drug-drug interactions and acute pancreatitis in the FDA adverse event reporting system: focus on incretin-based drugs.Frontiers in drug safety and regulation · 2026Article
- Drug combination choices of 5α-reductase inhibitors and α-blockers in patients with benign prostatic hyperplasia: a study based on the FAERS database.Frontiers in medicine · 2026Article
- Higher risk of gastrointestinal stenosis and obstruction in clozapine-treated individuals with schizophrenia: a pharmacovigilance study based on the FDA adverse event reporting system database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Hemorrhagic risk of concomitant direct oral anticoagulants and fluoroquinolones: integration of pharmacovigilance and therapeutic drug monitoring.Frontiers in pharmacology · 2026Article
- Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases.Frontiers in medicine · 2026Article
- A Dose-Aware Model for Revealing Dose-Risk Relationship of Drug-Drug Interaction.CPT: pharmacometrics & systems pharmacology · 2025Article
- Pharmacovigilance analysis of myopathy associated with azoles and nonstatins interactions based on US FAERS database.Scientific reports · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concomitant use of multiple drugs for therapeutic purposes is known as "polypharmacy situations," which has been recognized as an important social problem recently. In polypharmacy situations, each drug not only induces adverse events (AEs) but also increases the risk of AEs due to drug-drug interactions (DDIs). The proportion of AEs caused by DDIs is estimated to be around 30% of unexpected AEs. The randomized clinical trials in pre-marketing typically focus emphasis on the verification of single drug safety and efficacy rather than the surveys of DDI, and therefore, patients on multiple drugs are usually excluded. However, unlike pre-marketing randomized clinical trials, in clinical practice (= post marketing), many patients use multiple drugs. The spontaneous reporting system is one of the significant sources drug safety surveillance in post-marketing. Commonly, signals of potential drug-induced AEs detected from this source are validated in real-world settings. Recently, not only methodological studies on signal detection of "single" drug, but also on several methodological studies on signal detection of DDIs have been conducted. On the other hand, there are few articles that systematically summarize the statistical methodology for signal detection of DDIs. Therefore, this article reviews the studies on the latest statistical methodologies from classical methodologies for signal detection of DDIs using spontaneous reporting system. This article describes how to calculate for each detection method and the major findings from the published literatures about DDIs. Finally, this article presented several limitations related to the currently used methodologies for signal detection of DDIs and suggestions for further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.